Recent Updates
Recently added Catalysts
SIGA Negative Sentiment Score: 20/100

SIGA ALERT: Bragar Eagel & Squire, P.C. is Investigating SIGA Technologies, Inc. on Behalf of SIGA Stockholders and Encourages Investors to Contact the Firm

Key Takeaway: Bragar Eagel & Squire, P.C. is investigating SIGA Technologies, Inc. on behalf of its stockholders due to potential violations of federal securities laws. This follows the termination of the Chief Medical Officer, Dr. Jay Varma, which led to a significant drop in stock price. Additionally, a secretly recorded video surfaced, suggesting attempts to manipulate public perception of the TPOXX treatment for Monkeypox, resulting in further financial losses for investors.

Market Sentiment Analysis

CONCERNS & RISKS

  • SIGA's Chief Medical Officer was terminated, raising concerns about company governance.
  • A recorded video revealed efforts to mislead investors about TPOXX's efficacy for Monkeypox.
  • SIGA's stock price dropped significantly after both the termination announcement and the video disclosure.

Full Press Release Details

NEW YORK, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against SIGA Technologies, Inc. (“SIGA” or the “Company”) (NASDAQ: SIGA) on behalf of SIGA stockholders. Our investigation concerns whether SIGA has violated the federal securities laws and/or engaged in other unlawful business practices.
Click here to participate in the action.
On September 23, 2024, after market hours, SIGA disclosed that its Chief Medical Officer and Executive Vice President, Dr. Jay Varma, had been terminated from his position. On this news, SIGA’s stock price fell $0.42, or 5%, to close at $8.01 per share on September 24, 2024, thereby injuring investors.
Then, on September 25, 2024, a secretly recorded video surfaced online, revealing Varma detailing a media “spin” campaign to salvage TPOXX as a treatment for Monkeypox so that investors wouldn’t “dump the stock, thinking that the Company is worthless,” despite the admission that “in the United States, the risk [for Monkeypox] is very low.” On this news, SIGA’s stock price fell $1.26, or 15.7%, to close at $6.75 per share on September 25, 2024, thereby injuring investors further.
If you purchased or otherwise acquired SIGA shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.

Tags

Frequently Asked Questions

What is the investigation about SIGA Technologies, Inc.?

Bragar Eagel & Squire is investigating SIGA for potential violations of federal securities laws.

Why did SIGA's stock price drop recently?

The stock fell after the termination of CMO Dr. Jay Varma and subsequent revelations from a video.

How much did SIGA's stock fall on September 25, 2024?

On September 25, 2024, SIGA's stock price dropped by $1.26, a 15.7% decline.

Who can participate in the claims against SIGA?

Investors who acquired SIGA shares and suffered losses may participate in the claims.

How can I contact Bragar Eagel & Squire for more information?

You can email investigations@bespc.com or call (212) 355-4648 for inquiries.

Last updated: Oct 8, 2024